載入...
Application of anti-Sclerostin therapy in non-osteoporosis disease models
Sclerostin, a known inhibitor of the low density lipoprotein related protein 5 and 6 (LRP5 and LRP6) cell surface signaling receptors, is integral in the maintenance of normal bone mass and strength. Patients with loss of function mutations in SOST or missense mutations in LRP5 that prevent Sclerost...
Na minha lista:
| 發表在: | Bone |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5328800/ https://ncbi.nlm.nih.gov/pubmed/27780792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2016.10.018 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
載入...